British Bio confident
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BRITISH Bio-technology, which last week began second-phase testing of its Aids treatment, said it was 'a few million pounds' ahead of budget in making an interim loss of pounds 4.7m, writes Paul Durman.
The company, the UK's only listed bio-technology group, expects a larger second-half loss as it incurs the costs of further tests on its products. Besides the trials on the anti-Aids vaccine at St Mary's Hospital in London, its cancer and asthma drugs will also begin new tests soon.
The loss of pounds 4.7m in the six months to 31 October was a pounds 1m improvement on last year. James Noble, finance director, said the company was helped by the pounds 897,000 contribution from Glaxo towards testing its asthma treatment, BB-882.
Mr Noble said British Bio-technology was 'absolutely delighted' with the results of the initial testing of BB-882. The drug, which is administered in capsule form, is well tolerated and appears to offer lasting benefits.
After testing its products on healthy volunteers this year, the company is moving towards tests on affected patients. The Aids vaccine, p24- VLP, is the first to have reached this stage.
British Bio-technology raised pounds 30m when it came to the market in July and has pounds 55m on deposit.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments